PLEASANTON, Calif., Dec. 9, 2011 /PRNewswire/ -- Thoratec (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Oppenheimer & Co. 22nd Annual Healthcare Conference on Tuesday, December 13.
Taylor C. Harris, Senior Director of Investor Relations and Business Development, will provide an update on the company, beginning at 10:15 a.m., Eastern Standard Time (7:15 a.m., Pacific Standard Time). The presentation will be available through the conference web site at http://www.veracast.com/webcasts/opco/healthcare2011/82105477.cfm or on the company's web site at http://www.thoratec.com.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 18,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag® and PediMag®/PediVAS® product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web site at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate, HeartMate II and GoGear are registered trademarks of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH.